Compounds That Treat Malaria and Prevent Malaria Transmission


Malaria is the single leading cause of death, especially among children, in the developing world. Malaria is caused by infection with parasites of the genus Plasmodium, transmitted by mosquitos. In addition to transmission, vital steps in the parasite lifecycle occur in the mosquito host. The invention offered for licensing relates to therapeutic compounds and related pharmaceutical compositions that can be used in the prevention and treatment of malaria infection. More specifically, the invention is drawn to compounds that may kill sexual and mosquito stage malaria parasites to block transmission. Specifically claimed is the antihistamine Ketotifen, which has demonstrated activity blocking parasite development in mosquitoes. Also claimed are treatments encompassing Ketotifen with other existing antimalarial drugs in a combination treatment aimed at multiple stages in the malaria life cycle.

Potential Commercial Applications: Competitive Advantages:
  • Prevention and treatment of malaria infections.
 
  • Drugs that kill sexual and mosquito stages of the parasite are important for preventing and/or slowing the spread of malaria infection and ultimately for malaria eradication.
  • Primaquine, the only currently available drug shown to block transmission, is known to cause serious adverse side effects.


Inventors:

Xin-zhuan Su (NIAID)  ➽ more inventions...

Jing Yuan (NIAID)  ➽ more inventions...

Dipak Raj (NIAID)  ➽ more inventions...

Sittiporn Pattaradilokrat (NIAID)  ➽ more inventions...

Ronald Johnson (NCATS)  ➽ more inventions...

Ruili Huang (NCATS)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 9,375,424 issued 2016-06-28
US Application No. 15/192,779
US Application No. 13/392,668
US Application No. 61/237,417
Various international patent applications may also be available.

Publications:
Eastman RT, et al. PMID 23129054

Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Peter Tung at Peter.Tung@nih.gov or 240-669-5483.


Licensing Contact:
Peter Tung, Ph.D., M.B.A.
Email: peter.tung@nih.gov
Phone: 240-669-5483

OTT Reference No: E-283-2009/0
Updated: Jul 18, 2017